SIAP
RPRX icon

Sterling Investment Advisors (Pennsylvania)’s Royalty Pharma RPRX Stock Holding History

Sterling Investment Advisors (Pennsylvania)’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1
Closed – – 456
2020
Q2 		$0 Buy
+1
New +$49 ﹤0.01% 438

Other funds holding RPRX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sterling Investment Advisors (Pennsylvania)'s RPRX Position: Q3 2020 in Review

Sterling Investment Advisors (Pennsylvania) sold out of Royalty Pharma (RPRX) in Q3 2020, closing a stake of 1 share.

Sterling Investment Advisors (Pennsylvania) first reported a position in RPRX in Q2 2020 and held it in 1 quarter. The position peaked at $0 in Q2 2020. 134 funds tracked by Wall St. Rank hold RPRX as of Q3 2020.

  • Sterling Investment Advisors (Pennsylvania) reported no remaining Royalty Pharma position as of Q3 2020 after selling out during the quarter.
  • Sterling Investment Advisors (Pennsylvania) sold 1 Royalty Pharma share in Q3 2020.
  • Sterling Investment Advisors (Pennsylvania) first reported a position in Royalty Pharma in Q2 2020 and held it in 1 quarter.
  • Sterling Investment Advisors (Pennsylvania)'s Royalty Pharma position peaked at $0 in Q2 2020.
  • 134 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2020.

Based on Sterling Investment Advisors (Pennsylvania)'s 13F filing for Q3 2020, filed 26 Oct 2020.